ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ELUTIA INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.82+0.02 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $36.05M
- P/E (TTM)
- 0.9
- Dividend yield
- –
Share price
−$0.0755 (−8.48%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ELUTIA INC. saw revenue fall 0.3% to $12.14M over the twelve months to Jun 30, 2026. Free cash flow was -$46.03M.
Revenue
$12.14M
-0.3% vs. a year earlier
Operating income
-$26.07M
TTM Q2 2026
Free cash flow
-$46.03M
TTM Q2 2026
EPS, diluted
$0.87
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $36.05M
- P/E ratio
- 0.9
- Price to sales
- 2.97
- Price to book
- 2.29
- Dividend yield
- –
- Free cash flow yield
- -127.67%
Fundamentals
- Revenue
- $12.14M
- Net income
- $51.81M
- EPS, diluted
- $0.87
- Free cash flow
- -$46.03M
- Book value per share
- $0.36
- Diluted shares
- 44M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$12.14M-0.3% YoY
Gross profit
$7.02M+18.0% YoY
Operating income
-$26.07M
Net income
$51.81M
EPS, diluted
–
Free cash flow
-$46.03M
Reported periodTrailing twelve months